Zenas BioPharma, Inc.(ZBIO) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates -Completed initial public of ering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy- -Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related Disease (IgG4-RD)- -Advancing multiple obexelimab Phase 2 and Phase 3 clinical trials w ...